Largest Race-Based Survival Advantage to Date Seen in Men Receiving Sipuleucel-T for mCRPC

Leggi l'articolo originale


A subanalysis of the PROCEED trial showed a surprisingly high survival advantage for a particular race of men receiving immunotherapy for mCRPC.

Lascia un commento